Introduction. Cyclodextrins are used in various areas due to their ability to form inclusion complexes and to modify some properties of the guest molecule. The characteristics that can be improved are related to solubility of poorly water-soluble drugs, stabilization of labile guests against the degradative effects of environment (oxidation, light and heat), bioavailability, decreasing of side effects, taste modification or odour elimination and controlling of drug release. Also, ibuprofen is a very used nonsteroidal anti-inflammatory drug in treating pain and inflammation, but the long-term use of this drug has been associated with gastrointestinal side effects and nephrotoxicity. These led to introducing of new compounds of ibuprofen with improved profile. Aim. The research project combine two actual topics in pharmaceutical area: developing new safer drugs and improving the pharmacokinetic and pharmacotoxicological profile through complexation with cyclodextrins. The main objective was to develop drug delivery systems based on cyclodextrins and new ibuprofen thiazolidin-4-ones as potential analgesic and anti-inflammatory drugs. Materials and methods. Thiazolidin-4-one derivatives of ibuprofen were included in β-cyclodextrin complexes by co-precipitation (1:1M) and lyophilization methods. The inclusion complexes were characterized using spectral methods such as infrared analysis (FTIR), NMR spectroscopy and phase solubility studies. The surface morphology was studied using scanning electron microscopy (SEM). Results and conclusions. There were obtained and characterized 4 inclusion complexes with β-cyclodextrin and new ibuprofen derivatives with thiazolidin-4-one structure. These can confirm the theoretical premises for an improved pharmacological and safety toxicological profile and can continue with future studies (in vivo biological evaluation of pharmacokinetic, analgesic and anti-inflammatory profile).